Sanara MedTech (SMTI) Panoramica del titolo
Sanara MedTech Inc. è una società di tecnologia medica che sviluppa, commercializza e distribuisce soluzioni chirurgiche a medici, ospedali, cliniche e strutture di assistenza post-acuta negli Stati Uniti. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 4/6 |
| Crescita futura | 4/6 |
| Prestazioni passate | 2/6 |
| Salute finanziaria | 1/6 |
| Dividendi | 0/6 |
Premi
Analisi del rischio
SMTI Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Sanara MedTech Inc.
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | US$23.64 |
| Massimo di 52 settimane | US$35.95 |
| Minimo di 52 settimane | US$16.05 |
| Beta | 1.16 |
| Variazione di 1 mese | 19.39% |
| Variazione a 3 mesi | 15.60% |
| Variazione di 1 anno | -23.72% |
| Variazione a 3 anni | -32.82% |
| Variazione a 5 anni | -16.32% |
| Variazione dall'IPO | -97.48% |
Notizie e aggiornamenti recenti
Aggiornamento della narrazione • May 03
SMTI: Bullish Initiation And Cost Effectiveness Evidence Will Support Future Upside
Analysts have reaffirmed a $34.00 price target for Sanara MedTech, citing a fresh bullish initiation that highlights the company’s long term growth potential and supports unchanged assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E. Analyst Commentary Bullish Takeaways Bullish analysts view the reaffirmed US$34.00 target as supported by the current fair value framework, with assumptions on discount rate, revenue growth, profit margin, and future P/E kept intact.Aggiornamento della narrazione • Apr 19
SMTI: Bullish Coverage And Cost Effectiveness Study Will Support Future Upside
Analysts have reduced their price target on Sanara MedTech by $2 to $34. This reflects updated views on growth, profitability, and a higher assumed future P/E, following recent bullish Street initiation commentary.Recent updates
Aggiornamento della narrazione • May 03
SMTI: Bullish Initiation And Cost Effectiveness Evidence Will Support Future Upside
Analysts have reaffirmed a $34.00 price target for Sanara MedTech, citing a fresh bullish initiation that highlights the company’s long term growth potential and supports unchanged assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E. Analyst Commentary Bullish Takeaways Bullish analysts view the reaffirmed US$34.00 target as supported by the current fair value framework, with assumptions on discount rate, revenue growth, profit margin, and future P/E kept intact.Aggiornamento della narrazione • Apr 19
SMTI: Bullish Coverage And Cost Effectiveness Study Will Support Future Upside
Analysts have reduced their price target on Sanara MedTech by $2 to $34. This reflects updated views on growth, profitability, and a higher assumed future P/E, following recent bullish Street initiation commentary.Aggiornamento della narrazione • Mar 21
SMTI: Surgical Economics And Higher Margins Will Support Future Upside
Analysts have lowered their price target for Sanara MedTech from $40 to $36, citing revised fair value estimates, along with updated assumptions for revenue growth, profit margins, the discount rate and future P/E multiples. What's in the News A peer-reviewed study in the Journal of Medical Economics evaluates CellerateRX Surgical Powder as an add-on to standard care in high risk spinal surgery.Aggiornamento della narrazione • Mar 05
SMTI: New Revenue Guidance And Surgical Pipeline Will Support Future Upside
Analysts have kept Sanara MedTech's fair value estimate steady at $40.00 per share, with only marginal tweaks to the discount rate, revenue growth, profit margin, and future P/E inputs that reflect fine tuning rather than a change in overall conviction. What's in the News Sanara MedTech issued new guidance for the fourth quarter of 2025, with expected net revenue between $27.2 million and $27.7 million.Aggiornamento della narrazione • Feb 19
SMTI: Surgical Portfolio And Guidance Will Support Future Upside Potential
Analysts have maintained their $40.00 price target for Sanara MedTech, citing only very small adjustments to assumptions such as discount rate, long term revenue growth, profit margin and future P/E that did not materially change their overall valuation view. What's in the News Issued revenue guidance for Q4 2025, with expected net revenue in a range of $27.2 million to $27.7 million and commentary on the impact of approximately $1.8 million of BIASURGE sales in Q4 2024 on year over year comparisons (Corporate Guidance).Aggiornamento della narrazione • Feb 04
SMTI: Core Surgical Focus Will Drive Future Upside Potential
Analysts have modestly adjusted their price target for Sanara MedTech to US$40.00. This reflects small updates to assumptions around discount rate, revenue growth, profit margin and future P/E that keep their overall valuation view essentially unchanged.Aggiornamento della narrazione • Jan 21
SMTI: Core Surgical Focus And Orthopedic Alliance Will Drive Future Upside Potential
Analysts have trimmed their price target on Sanara MedTech from US$41 to US$40, reflecting updated assumptions around profit margins and future P/E expectations while keeping the overall long term growth story intact. What's in the News BIASURGE Advanced Surgical Solution received an Innovative Technology contract from Vizient Inc., signaling unique product qualities recognized by hospital experts on Vizient's client led councils (Key Developments).Aggiornamento della narrazione • Jan 07
SMTI: Core Surgical Focus And Orthopedic Alliance Will Drive Future Upside Potential
Analysts have kept their fair value estimate for Sanara MedTech steady at US$41.00. This reflects only small tweaks to their underlying assumptions on discount rate, revenue growth, profit margin and future P/E that do not materially alter their overall view on the stock.Aggiornamento della narrazione • Dec 14
SMTI: Core Surgical Focus Will Drive Future Profit Expansion And Upside Potential
Analysts have raised their price target for Sanara MedTech to approximately $41.00 per share, reflecting slightly lower discount rate assumptions and a marginally improved outlook for the company’s long term valuation multiples. What's in the News Sanara MedTech and Biomimetic Innovations provided an update on their strategic alliance focused on advancing orthopedic solutions and commercial readiness for new products (Key Developments).Aggiornamento della narrazione • Nov 29
SMTI: Leadership Transition And Discontinued Operations Will Drive Profit Expansion Ahead
Analysts have reiterated their previous price target for Sanara MedTech at $41.00. They cite minimal changes in key financial assumptions and maintain a stable outlook for the company.Aggiornamento della narrazione • Nov 15
SMTI: Leadership Transition And Streamlined Operations Will Drive Profitability Expansion
Narrative Update on Sanara MedTech: Analyst Price Target Revision Analysts have lowered their price target for Sanara MedTech from $50.00 to $41.00, citing updated estimates for key valuation metrics and a moderation in projected revenue growth. What's in the News Sanara MedTech is discontinuing operations of Tissue Health Plus (THP) to improve operating efficiency and will reclassify THP as discontinued operations in financial statements.Articolo di analisi • Aug 13
Sanara MedTech Inc. (NASDAQ:SMTI) Doing What It Can To Lift Shares
With a median price-to-sales (or "P/S") ratio of close to 2.7x in the Medical Equipment industry in the United States...
Nuova narrazione • Mar 31
Tissue Health Plus And OsStic Will Expand Market Reach
Expansion in sales coverage and partnerships aims to boost product adoption, enhancing revenue in both new and existing markets.Seeking Alpha • Jan 30
Sanara MedTech: A Promising Growth Story At An Attractive Valuation
Summary Shares have risen nearly 15% since the company posted preliminary Q4 results, which showed revenue up by 45-48% year over year. While growth was boosted by one-off demand for its BIASURGE product, underlying growth was still strong at 37%. There remains a long runway for growth for its surgical products, with the potential for this to be augmented by other growth drivers, including inorganic opportunities. While the surgical segment is solidly profitable, overall profitability is depressed by losses in Sanara’s pre-commercialization segment. At 3 times revenue, I find the current valuation attractive, and hence I am assigning shares a Buy rating. Read the full article on Seeking AlphaArticolo di analisi • Dec 19
Sanara MedTech (NASDAQ:SMTI) Is Carrying A Fair Bit Of Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Articolo di analisi • Nov 15
US$44.00: That's What Analysts Think Sanara MedTech Inc. (NASDAQ:SMTI) Is Worth After Its Latest Results
Sanara MedTech Inc. ( NASDAQ:SMTI ) defied analyst predictions to release its quarterly results, which were ahead of...Articolo di analisi • Sep 05
Sanara MedTech Inc. (NASDAQ:SMTI) Looks Just Right With A 28% Price Jump
Sanara MedTech Inc. ( NASDAQ:SMTI ) shares have had a really impressive month, gaining 28% after a shaky period...Articolo di analisi • Aug 14
Here's Why Sanara MedTech (NASDAQ:SMTI) Can Afford Some Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Articolo di analisi • May 23
Sanara MedTech Inc.'s (NASDAQ:SMTI) Shares Not Telling The Full Story
There wouldn't be many who think Sanara MedTech Inc.'s ( NASDAQ:SMTI ) price-to-sales (or "P/S") ratio of 3.8x is worth...Articolo di analisi • Nov 15
Is Sanara MedTech (NASDAQ:SMTI) Using Too Much Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Articolo di analisi • May 22
Investors Still Waiting For A Pull Back In Sanara MedTech Inc. (NASDAQ:SMTI)
You may think that with a price-to-sales (or "P/S") ratio of 5.8x Sanara MedTech Inc. ( NASDAQ:SMTI ) is a stock to...Articolo di analisi • Mar 22
Sanara MedTech Inc. (NASDAQ:SMTI) Analysts Are Pretty Bullish On The Stock After Recent Results
Sanara MedTech Inc. ( NASDAQ:SMTI ) last week reported its latest annual results, which makes it a good time for...Seeking Alpha • Sep 06
Sanara MedTech: Differentiated Offering With Niche Wound Care Exposure
Summary Sanara MedTech has caught a bid since the June roll and looks attractively priced at its current market cap. Q2 earnings were strong and demonstrated the company is capturing market share. We see shares offer a 25% pricing asymmetry to the upside based on forward-looking sales multiples. We rate SMTI a buy. Investment summary We continue to see selective opportunities within US medical devices as investors look to shift up the quality spectrum. One such name is Sanara MedTech Inc. (SMTI), a differentiated offering with niche exposure to wound care. The primary value proposition lies within the Cellerate portfolio, however, there looks to be a gap in current fundamentals to forward expectations. This has created a pricing asymmetry to the upside where we see shares fairly valued at $39. Rate buy on these factors. Q2 earnings comments The company derives the bulk of revenue volume from sales of the CellerateRX surgical powder. This is a hydrolyzed collagen that is indicated for surgical and non-surgical wound care, burns included. Collagen actually plays an important role in tissue healing throughout all stages of repair. There are numerous studies corroborating its efficacy in these applications. Globally, the hydrolyzed collagen market was recently valued at US$1.09 billion and was forecast to climb at a CAGR of 7.8% by 2032 to a market value of US$2.34 billion. CellerateRX is a long-term compounder with exciting economics tied into the mix by our estimation. By the end of Q2, it was being sold in ~590 hospitals and ambulatory centres in 27 states. It is approved to be sold in a total of 1,580 facilities. Management estimates the total addressable market for CellerateRX, measured in terms of hospitals and ambulatory centres, is ~12,000 facilities in the US. Net quarterly revenues of $9.7 million ("mm") grew 54% YoY and was comprised primarily of organic growth. For the six months to date, revenue was $17.5mm, meaning the bolus of revenue was generated in Q2. The increase in sales was underscored by continued adoption of the Cellerate portfolio throughout the quarter. The gain of 54% is well above market growth trends and suggests to us that SMTI captured additional market share during the quarter. The Scendia Biologics acquisition was also completed and this adds an entire suite of complementary biologics products and tuck-ins to the Cellerate portfolio. In particular, the acquisition looks accretive to the company's cellular and bone matrix offerings, Amplify and Allocyte. These are differentiated offerings in a complex segment of osteo-cartilaginous tissue repair, where treatment failure rates are high. Scendia clipped revenue of $8.3mm in FY21. SMTI's goal is to expand Scendia into an additional 18 states and eventually reach all 50 states. We estimate the deal to show accretion to the bottom line as early as the next quarter. Reconciliations to GAAP earnings Considering where SMTI allocated capital during the past 12 months and last quarter, several adjustments to GAAP earnings must be made in order to understand how much the company invested, where it allocated capital and the return on this investment. As seen in Exhibit 1, we have capitalized 100% if the R&D investment and reconciled $412,000 in non-cash spend that was expensed on the income statement. This results in an improved operating loss and net loss to $1.06mm and $1.12mm respectively. In consequence, we estimate non-GAAP quarterly earnings to be at a negative $0.14 per share for the company. These adjustments also see a shift in shareholder equity up from $35.45mm to $35.86mm. Exhibit 1. Reconciled earnings from GAAP accounting reveal narrower net-loss and improved EPS. Data: SMTI 10-Q Q2 FY22 Factors to consider for valuation Measures of value are where the risk/reward calculus begins to turn bullish for STMI in our estimation. As seen below in Exhibit 2, these are high quality assets we are buying into, with liabilities made up of accruals and operating leases. The absence of a goodwill ledger on the balance sheet presents a clean asset value. Pleasingly, inventory value only saw a marginal increase YoY whilst inventory turnover was flat at 2x. Following acquisitions made throughout the year, the company booked growth of 359% YoY in intangible asset value, lifting total assets and book value by more than $10mm. As seen in Exhibit 3, clarity is provided on the fair value of these investments. We are satisfied there is validity in the fair value of these investments, and note the $1.6mm amortization schedule on a straight line basis. Exhibit 2. Note the absence of goodwill, despite recent acquisitions and increase to intangible asset value. This is a 'clean' balance sheet that can continue to be put to effective use, by estimation. Data: SMTI 10-Q Q2 FY22 Exhibit 3. SMTI intangibles are well-defined, and validate their presence on the balance sheet. This is essential as oftentimes intangibles are booked precariously and do not warrant inclusion in measures of corporate value.Seeking Alpha • Aug 15
Sanara MedTech reports Q2 results
Sanara MedTech press release (NASDAQ:SMTI): Q2Revenue of $9.7M (+54.5% Y/Y) beats by $1M. Net loss of $3.3 millionRendimenti per gli azionisti
| SMTI | US Medical Equipment | US Mercato | |
|---|---|---|---|
| 7D | 9.2% | 3.0% | -0.8% |
| 1Y | -23.7% | -18.3% | 27.1% |
Ritorno vs Industria: SMTI ha avuto una performance inferiore rispetto al US Medical Equipment che ha registrato un rendimento -18.3 % nell'ultimo anno.
Rendimento vs Mercato: SMTI ha avuto una performance inferiore al mercato US che ha registrato un rendimento 27.1 % nell'ultimo anno.
Volatilità dei prezzi
| SMTI volatility | |
|---|---|
| SMTI Average Weekly Movement | 9.1% |
| Medical Equipment Industry Average Movement | 8.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
Prezzo delle azioni stabile: SMTI non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato US.
Volatilità nel tempo: La volatilità settimanale ( 9% ) di SMTI è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 2001 | 108 | Seth Yon | sanaramedtech.com |
Sanara MedTech Inc. è una società di tecnologia medica che sviluppa, commercializza e distribuisce soluzioni chirurgiche a medici, ospedali, cliniche e strutture di assistenza post-acuta negli Stati Uniti. L'azienda offre CellerateRX Surgical, un idrolizzato medico di collagene bovino di tipo I indicato per la gestione di ferite chirurgiche, traumatiche, parziali e a tutto spessore, nonché di ustioni di primo e secondo grado. L'azienda sviluppa anche BIASURGE, una soluzione chirurgica senza risciacquo utilizzata per l'irrigazione delle ferite; FORTIFY Tissue Repair Graft (FORTIFY TRG), un foglio di matrice extracellulare multistrato liofilizzato della sottomucosa intestinale di piccole dimensioni; BiFORM, un impianto osteoconduttivo, bioattivo e poroso che consente la crescita ossea attraverso il sito dell'innesto e può essere utilizzato come striscia o modellato in un mastice per riempire un difetto osseo; ACTIGEN Inductive Bone Matrix, una matrice di allotrapianto differenziata di derivazione naturale con proprietà di manipolazione robuste; ALLOCYTE Plus, una matrice ossea cellulare di allotrapianto umano contenente cellule progenitrici di derivazione ossea e fibre ossee conformabili; e TEXAGEN, un allotrapianto di membrana amniotica multistrato utilizzato come barriera anatomica con una manipolazione robusta che può essere suturata per il fissaggio.
Sanara MedTech Inc. Riepilogo dei fondamenti
| SMTI statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | US$210.77m |
| Utili (TTM) | US$630.72k |
| Ricavi(TTM) | US$107.48m |
343.5x
Rapporto P/E2.0x
Rapporto P/SSMTI è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| SMTI Conto economico (TTM) | |
|---|---|
| Ricavi | US$107.48m |
| Costo del fatturato | US$7.61m |
| Profitto lordo | US$99.87m |
| Altre spese | US$99.24m |
| Utili | US$630.72k |
Ultimi utili riportati
Mar 31, 2026
Prossima data di guadagno
n/a
| Utile per azione (EPS) | 0.069 |
| Margine lordo | 92.92% |
| Margine di profitto netto | 0.59% |
| Rapporto debito/patrimonio netto | 658.5% |
Come si è comportato SMTI nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/21 14:18 |
| Prezzo dell'azione a fine giornata | 2026/05/21 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Sanara MedTech Inc. è coperta da 2 analisti. 2 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Yi Chen | H.C. Wainwright & Co. |
| Frank Takkinen | Lake Street Capital Markets, LLC |